



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Letter to the Editor

In vitro potency of amikacin against carbapenem-resistant *Pseudomonas aeruginosa*: A target for nebulization strategy?

Gabriel T. Cuba ^{a,b,1,*}, Paulo H.D. Santos ^{a,1}, Antonio C.C. Pignatari ^a, David P. Nicolau ^c, Carlos R.V. Kiffer ^a

^a Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicina, São Paulo, SP, Brazil

^b Universidade de São Paulo (HCFMUSP), Hospital das Clínicas, Faculdade de Medicina, São Paulo, SP, Brazil

^c Center of Anti-infective Research and Development, Hartford Hospital, Hartford, CT, United States

ARTICLE INFO

Article history:

Received 12 December 2021

Accepted 4 April 2022

Available online 28 April 2022

Dear Editor,

Pharmacodynamic model simulating amikacin epithelial lining fluid exposures showed that inhaled amikacin monotherapy provided bactericidal activity against isolates tested at MICs ≤ 256 mg/L.¹ Then, we decided to investigate the *in vitro* potency of amikacin against Carbapenem-Resistant *P. aeruginosa* (CRPA) isolates representative from Brazilian ICU settings. Seventy-one (71) non-duplicate isolates of *P. aeruginosa* from 10 different ICUs from Brazil were included.² *P. aeruginosa* were recovered from nosocomial bloodstream ($n = 47$, 66.2%) and respiratory tract ($n = 24$, 33.8%). Approximately two-thirds of the patients were male ($n = 47$, 66.2%) and had a mean age of 57 ± 18.2 years (range, 5 to 83 years).

The presence of 16S RNA methyltransferase-encoding genes (*armA*, *rmtD*, and *rmtB*) was evaluated by Real Time Polymerase Chain Reaction (RT-PCR) using the Rotor-Gene Q (Qiagen, Germany) and High-Resolution Melt-HRM

master mix (HRM PCR buffer type, EvaGreen dye, Qiagen, Germany). The identification was performed by multiplex RT-PCR using specific primers of each gene (*armA*, *rmtB* and *rmtD*) as previously described.³ The detection of metallo-beta-lactamase-encoding-genes *bla*_{SPM-1}, *bla*_{TMP} and *bla*_{VIM} was performed by a Multiplex Real Time PCR as previously described. The presence of *bla*_{SPM-1} was confirmed by a single RT-PCR using the primer pair previously described by Mendes and colleagues.⁴

The Susceptibility Testing (AST) for amikacin (Sigma-Aldrich, St. Louis, USA) was performed by agar dilution and the results were interpreted according to Clinical and Laboratory Standards Institute (CLSI),^{3,5,6} with amikacin concentration ranging from 0.25 to > 4096 mg/L and meropenem from 16 to 512 mg/L. Isolates with amikacin MIC > 16 mg/L were selected for 16S RNA methyltransferase and metallo-beta-lactamase testing by polymerase chain reaction.^{4,7}

MIC by AD distribution for amikacin and meropenem is shown in Fig. 1. Forty-seven isolates with amikacin MIC > 16 mg/L were submitted to 16S RNA methyltransferase-encoding and metallo-beta-lactamase-encoding gene

* Corresponding author.

E-mail address: gbtrova@gmail.com (G.T. Cuba).

¹ Authors equally contributed to this work.

<https://doi.org/10.1016/j.bjid.2022.102355>

1413-8670/© 2022 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>)




Fig. 1 – Distribution of MIC frequency of Amikacin (a) and Meropenem (b) against carbapenem-resistant *P. aeruginosa*.

detection. Forty-one (87.2%) isolates presented *rmtD*. Twenty-one (21/47; 44.7%) of those isolates presented *bla*_{SPM-1}. Amikacin MICs $\geq 4,096$ mg/L was found among 19/21 isolates co-producing *bla*_{SPM-1} and *rmtD* genes and among only 9/26 isolates *bla*_{SPM-1} negative and *rmtD* positive. Higher meropenem MICs (64 to 512 mg/L) were observed more commonly among SPM-1-producers isolates (16/22; 72.7%) while 80% (20/25) of the isolates with lower meropenem MICs (16 to 32 mg/L) did not produce any metallo-beta-lactamase. Higher meropenem MICs were already associated with metallo-beta-lactamase production, including SPM-1.⁷

For patients with VAP due to Gram-negative bacilli that are susceptible to only last resort drugs, adjunctive inhaled antibiotic associated with systemic antibiotics could be prescribed. However, aminoglycoside monotherapy is not recommended to be used to treat patients with HAP/VAP due to *P. aeruginosa*.⁸ This study aimed at understanding the amikacin potency against clinically significant and resistant *P. aeruginosa*, representing difficult-to-treat respiratory infections with antimicrobial concentrations virtually unachievable by standard intravenous treatments. Approximately two thirds (61%) of those isolates included in this collection had MICs ≤ 256 mg/L and thus may be suitable to treatment using amikacin via the nebulization route. Nonetheless, 16S rRNA methyltransferase *RmtD* dissemination throughout Brazil associated to SPM production narrows the potential usefulness of aminoglycosides as a treatment option for salvage therapy of VAP and HAP caused by carbapenem-resistant *P. aeruginosa*.

Conflicts of interest

The authors declare no conflicts of interest.

REFERENCES

1. So W, Crandon JL, Hamada Y, Nicolau DP. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem. *J Antimicrob Chemother.* 2016;71:428–37.
2. Marra AR, Camargo LFA, Pignatari ACC, et al. Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study. *J Clin Microbiol.* 2011;49:1866–71.
3. Corrêa LL, Montezzi LF, Bonelli RR, Moreira BM, Picão RC. Revised and updated multiplex PCR targeting acquired 16S rRNA methyltransferases. *Int J Antimicrob Agents.* 2014;43:479–81.
4. Mendes RE, Kiyota KA, Monteiro J, et al. Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. *J Clin Microbiol.* 2007;45:544–7.
5. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017
6. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 11th ed. CLSI standard M07. Wayne, PA: Clinical and Laboratory Standards Institute; 2018
7. Cuba GT, Rocha-Santos G, Cayô R, et al. In vitro synergy of ceftolozane/tazobactam in combination with fosfomicin or aztreonam against MDR *Pseudomonas aeruginosa*. *J Antimicrob Chemother.* 2020;75:1874–8.
8. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis.* 2016;63:e61–111.